Has pharmaceutical innovation reduced social security disability growth?

International Journal of the Economics of Business

Volumn 18, Issue 2, 2011, Pages 293-316

  Lichtenberg, Frank R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Disability social security; Innovation; Pharmaceutical

Indexed keywords

EID: 79961159062     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/13571516.2011.584432     Document Type: Article

References (24)

1. Autor, David H., and Duggan, Mark G. (2003) The rise in the disability rolls and the decline in unemployment, Quarterly Journal of Economics, 118, pp. 157-205.
2. Bartik, Timothy (1991) Who Benefits from State and Local Economic Development Policies? (Kalamazoo, Michigan: W.E. Upjohn Institute for Employment Research).
3. Benitez-Silva, Hugo, Buchinsky, Moshe, Chan, Hiu Man, Cheidvasser, Sofia, and Rust, John (2000) how large is the bias in self-reported disability? NBER Working Paper 7526, February.
4. Bhattacharya, J., Goldman, D., and Sood, N. (2003) The link between public and private insurance and HIV-related mortality, Journal of Health Economics, 22, pp. 1105-22.
5. Blanchard, Olivier Jean, and Katz, Lawrence F. (1991) Regional evolutions, Brookings Papers on Economic Activity, 1, 1992, pp. 1-75.
6. Bound, John, and Holzer, Harry J. (2000) Demand shifts, population adjustments and labor market outcomes during the 1980s, Journal of Labor Economics, 18(1), pp. 20-54.
7. Costa, Dora L. (2000) Long-term declines in disability among older men: medical care, public health, and occupational change, National Bureau of Economic Research Working Paper 7605, March. Available at: http://www.nber.org/papers/w7605.
8. Dehejia, Rajeev H., and Wahba, Sadek (2002) Propensity score-matching methods for nonexperimental causal studies, Review of Economics and Statistics, 84, pp. 151-61. Available at: http://www.nber.org/'rdehejia/papers/matching.pdf.
9. Duggan, Mark G., and Evans, William N. (2008) Estimating the impact of medical innovation: a case study of HIV antiretroviral treatments, Forum for Health Economics & Policy, 11 (Economics of the HIV Epidemic), Article 1. Available at: http://www.bepress.com/fhep/11/2/1
10. Goldman, Dana P., Shang, Baoping, Bhattacharya, Jayanta, Garber, Alan M., Hurd, Michael, Joyce, Geoffrey F., Lakdawalla, Darius N., Panis, Constantijn, and Shekelle, Paul G. (2005) Consequences of health trends and medical innovation for the future elderly: health and costs of the future elderly, Health Affairs Web Exclusive Collection, 24.
11. Labriola, Merete, and Lund, Thomas (2007) Self-reported sickness absence as a risk marker of future disability pension. Prospective findings from the DWECS/DREAM study 1990-2004, Int J Med Sci, 4, pp. 153-8.
12. Lichtenberg, Frank (2005) Availability of new drugs and Americans' ability to work, Journal of Occupational and Environmental Medicine, 47, pp. 373-80.
13. Lichtenberg, Frank (2006a) The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997-2003, Pharmacoeconomics, 24(Suppl 3), pp. 5-25.
14. Lichtenberg, Frank (2006b) The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data, Expert Review of Pharmacoeconomics and Outcomes Research, 6, pp. 425-36.
15. Lichtenberg, Frank (2009) Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries 1995-2003, Health Economics, 18, pp. 519-34.
16. Lichtenberg, Frank (2010) The quality of medical care, behavioral risk factors, and longevity growth, Int J Health Care Finance Econ, 11, pp. 1-34.
17. Lichtenberg, Frank, and Sun, Shawn (2007) The impact of Medicare Part D on prescription drug use by the elderly: evidence from a large retail pharmacy chain, Health Affairs, 26, pp. 1735-44.
18. Lichtenberg, Frank, and Virabhak, Suchin (2007) Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'equipment for your health', Managerial and Decision Economics, 28, pp. 371-92.
19. Manton, K.G., Gu, X., and Lamb, V.L. (2006) Change in chronic disability from 1982 to 2004/2005 as measured by long-term changes in function and health in the US elderly population, Proc Natl Acad Sci USA, 103, pp. 18374-.
20. Sampat, Bhaven., and Lichtenberg, Frank R. (2011) What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 30, pp. 332-9.
21. Shekelle, Paul G., Ortiz, Eduardo, Newberry, Sydne J., Rich, Michael W., Rhodes, Shannon L., Brook, Robert H., and Goldman, Dana P. (2005) Identifying potential health care innovations for the elderly of the future: health and costs of the future elderly, Health Affairs Web Exclusive Collection, 24.
22. Social Security Administration, Office of Policy (2003) Annual Statistical Report on the Social Security Disability Insurance Program, SSA Publication 13-11826.
23. Virabhak, S., and Shinogle, J.A. (2005) Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana, American Journal of Managed Care, 11, January, Spec No: SP14-20.
24. Wang, Y. Richard, Pauly, Mark V., and Lin, Y. Aileen (2003) Impact of Maine's Medicaid drug formulary change on non-medicaid markets: spillover effects of a restrictive drug formulary, American Journal of Managed Care, 9, pp. 686-9.